News

Risk of Venous Thromboembolism and CV Events during Targeted Treatment of Nonspecific Bowel Inflammations

22. 8. 2022 Source: Intestinal Inflammations

Authors of a freshly published study based on real-world data from the USA investigated whether there are differences in the risk of venous thromboembolism (VTE) and major cardiovascular (CV) events in patients with nonspecific bowel inflammations (IBD) who were newly prescribed the Janus kinase inhibitor (JAK) tofacitinib or the tumor necrosis factor-alpha (TNF-α) inhibitor.

Comparison of the Efficacy of Tofacitinib and Vedolizumab in the Treatment of Ulcerative Colitis After Anti-TNF Therapy Failure

Therapeutic options for ulcerative colitis resistant to anti-TNF-α antibody treatment are available, but there were no studies comparing the selective immunosuppressants tofacitinib and vedolizumab…

21. 8. 2022 Source: Intestinal Inflammations

Bone density in hemophiliacs −⁠ known and less-known risk factors

Osteopenia or osteoporosis are known comorbidities of hemophilia and concern many of these patients. What all contributes to their development?

20. 8. 2022 Source: Hemophilia

Turoctocog Alfa in Tertiary Prophylaxis of Hemophilia A or Is It Always About Bleeding? Case Studies

This case report from our own practice concerns our experience with the treatment of hemophilia A with turoctocog alfa. The intention is, among other things, to compare different outcomes in our two…

19. 8. 2022 Source: Hemophilia with Movement

Nearly 20 Years with Bevacizumab Has Brought Hope for Patients and Deeper Understanding of Solid Tumors

Bevacizumab is among the first targeted therapies used in oncology. For many indications where chemotherapy options had been exhausted and few other treatment modalities were available, it changed…

19. 8. 2022 Source: Oncological Treatment

Lurasidone in Antipsychotic Therapy –⁠ A Case Study of a Virtual Patient from the Laurie Project

MUDr. Elis Bartečků, Ph.D., from the Department of Psychiatry at MU LF and FN Brno presented the current possibilities of telemedical education at the XIV congress of the Psychiatric Society of the…

18. 8. 2022 Source: Modern Treatment of Schizophrenia

Complex Impacts of Obesity on the Brains of People with Psychiatric Disorders

Obesity in individuals with bipolar disorder or schizophrenia is closely linked not only to higher mortality but also to worse progression of the psychiatric illness, lower response to psychiatric…

18. 8. 2022 Source: Modern Treatment of Schizophrenia

Time is Blood! Impact of Diagnostic Delays on Prognosis of Patients with Acquired Hemophilia A

The famous slogan of neurologists in connection with strokes –⁠ 'Time is brain!' –⁠ can be modified to 'Time is blood!' for the issue of acquired hemophilia A (AHA). The factor of time plays a crucial…

16. 8. 2022 Source: Hemophilia

Treatment of Depression with Persistent Severe Insomnia −⁠ Interactive Case Study

A 39-year-old patient comes to the psychiatric office due to depressive symptoms with anxiety and insomnia. He is worried about failing at work, also concerned about psychopharmaceuticals and their…

11. 8. 2022 Source: Depression and Anxiety

Urgent Administration of Romiplostim in Life-Threatening Bleeding Associated with ITP

Recommendations for the care of acute, especially major bleeding in individuals with severe immune thrombocytopenia (ITP) are not entirely clear. Various methods (steroid boluses, intravenous…

10. 8. 2022 Source: Immune Thrombocytopenia

Consensus on the Administration of TPO-RA as Second-Line Therapy in ITP

What is the role of thrombopoietin receptor agonists (TPO-RA) in the second line treatment of patients with immune thrombocytopenia (ITP)? Italian authors conducted a survey using the Delphi method…

10. 8. 2022 Source: Immune Thrombocytopenia

Brentuximab vedotin in combination with lenalidomide and rituximab in R/R DLBCL –⁠ results from the open part of the ECHELON-3 study

The aim of the open run-in phase of the randomized placebo-controlled phase III ECHELON-3 study, the results of which were presented at the ASCO and EHA 2022 congresses, was to evaluate the efficacy…

10. 8. 2022 Source: Hematologic Malignancies

pacient s klasickým Hodgkinovým lymfomem

6-year data from the ECHELON-1 study: How does combining brentuximab vedotin with chemotherapy affect overall survival of previously untreated cHL patients?

At this year's annual congress of the European Hematology Association (EHA), results from the analysis of 6-year data from the international randomized open-label phase III ECHELON-1 study on overall…

10. 8. 2022 Source: Hematologic Malignancies

How to Save a Leg from Amputation?

Feared complications in diabetics include defects in typical locations on the lower limbs. Their presence and frequent recurrences increase the risk of possible amputation of varying degrees, mainly…

10. 8. 2022 Source: Wound Healing

Prophylaxis EHL products FVIII bring improvements in clinical and pharmacokinetic results

A freshly published real-world clinical practice study from Spain highlights the experience of switching patients with hemophilia A in a prophylaxis setting from standard half-life products to newer…

8. 8. 2022 Source: Hemophilia

1 … 47 48 49 50 51 … 115

Back Filter by speciality

Remove filters

Popular this week